Anti- NTPDase1/CD39 antibodies inhibiting conversion of extracellular ATP to AMP show potent anti-tumor activity since they do not only reduce adenosine concentration but also trigger the ATP-P2X7R-NLRP3 inflammasome-IL-18 axis. This evidence concerns the gene IL18 and neoplasm.